OceanWorks International competitors

Richard A Miller is a co-founder, the president, and chief executive officer of [Corvus Pharmaceuticals](https://www.crunchbase.com/organization/corvus-pharmaceuticals#/entity), a clinical-stage biopharmaceutical company focused on the development of novel agents. Previously, he co-founded Pharmacyclics and served the same company as the chief executive officer. At Pharmacyclics, he led the initial discovery and development efforts for ibrutinib. Prior to co-founding Pharmacyclics, Miller co-founded IDEC and held various leadership roles as vice president and director at the same company. He has also founded other private and public biotech companies. Miller holds a Doctor of Medicine degree, summa cum laude, from the State University of New York Medical School and is currently Adjunct Clinical Professor of Medicine at Stanford University Medical Center.

Steve Miller is a Chief Executive Officer at Bulk Handling Systems.

J have worked as Chairman/Pres/CEO/Secy/Co-Founder at Genprex Inc. They work or have worked as MEMBER at STATE BAR OF TEXAS. J attended TAMU and University of Texas School of Law.

Constantino Nicolaou is a CEO at PANELCLAW INC.

James Fairbairn has 20+ years in senior finance roles with emerging companies. He is a Chartered Professional Accountant, having obtained his CPA designation in 1987 and is an Institute-certified Director. Jim holds a Bachelor of Arts from the University of Western Ontario. He is a director of several junior listed companies.

Dr. Randall Schatzman, Ph.D., chief executive officer and board member, joined Bolt Biotherapeutics in 2019 with over 30 years of biotechnology experience. Prior to Bolt, Dr. Schatzman was president and CEO, co-founder and board member of Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), from 2004 to 2018. Dr. Schatzman and his scientific team co-founded Alder in 2004 and led the company through the discovery and patenting of two monoclonal antibody therapeutics: eptinezumab, now in registration at FDA for migraine prevention and clazakizumab, being developed by Vitaeris for treatment of antibody-mediated kidney allograft failure. Prior to co-founding Alder, Dr. Schatzman was senior vice president of discovery research at Celltech R&D where the team discovered romosozumab which was subsequently licensed to Amgen in a 50/50 partnership. Prior to joining Celltech, he was at Syntex/Roche Bioscience where he served as preclinical team leader for Cytovene and team leader for Valcyte, both of which are now currently marketed drugs. Dr. Schatzman received his Ph.D. in Molecular Pharmacology from Emory University before completing an American Cancer Society postdoctoral fellowship in the laboratory of J. Michael Bishop at the University of California, San Francisco. Dr. Schatzman is an inventor on over 30 issued patents and is an author on more than 40 peer reviewed scientific publications.